Austin Health

Title
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.
Publication Date
2019-09-17
Author(s)
Hadoux, Xavier
Hui, Flora
Lim, Jeremiah K H
Masters, Colin L
Pébay, Alice
Chevalier, Sophie
Ha, Jason
Loi, Samantha
Fowler, Christopher J
Rowe, Christopher C
Villemagne, Victor L
Taylor, Edward N
Fluke, Christopher
Soucy, Jean-Paul
Lesage, Frédéric
Sylvestre, Jean-Philippe
Rosa-Neto, Pedro
Mathotaarachchi, Sulantha
Gauthier, Serge
Nasreddine, Ziad S
Arbour, Jean Daniel
Rhéaume, Marc-André
Beaulieu, Sylvain
Dirani, Mohamed
Nguyen, Christine T O
Bui, Bang V
Williamson, Robert
Crowston, Jonathan G
van Wijngaarden, Peter
Type of document
Journal Article
OrcId
0000-0002-4524-3706
0000-0003-2218-9951
0000-0002-4694-9479
0000-0002-7408-9453
0000-0002-4953-4500
0000-0003-0961-2321
0000-0001-9116-1376
0000-0002-3298-3086
0000-0003-3910-2453
DOI
10.1038/s41467-019-12242-1
Abstract
Studies of rodent models of Alzheimer's disease (AD) and of human tissues suggest that the retinal changes that occur in AD, including the accumulation of amyloid beta (Aβ), may serve as surrogate markers of brain Aβ levels. As Aβ has a wavelength-dependent effect on light scatter, we investigate the potential for in vivo retinal hyperspectral imaging to serve as a biomarker of brain Aβ. Significant differences in the retinal reflectance spectra are found between individuals with high Aβ burden on brain PET imaging and mild cognitive impairment (n = 15), and age-matched PET-negative controls (n = 20). Retinal imaging scores are correlated with brain Aβ loads. The findings are validated in an independent cohort, using a second hyperspectral camera. A similar spectral difference is found between control and 5xFAD transgenic mice that accumulate Aβ in the brain and retina. These findings indicate that retinal hyperspectral imaging may predict brain Aβ load.
Link
Citation
Nature Communications 2019; 10(1): 4227
Jornal Title
Nature Communications

Files:

NameSizeformatDescriptionLink